Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
June 11, 2021 12:30 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
June 09, 2021 16:05 ET
|
Zynerba Pharmaceuticals, Inc.
– 46.4% of shares voted, quorum not established to hold annual meeting – – Meeting scheduled to reconvene June 29, 2021 at 9:00 AM EDT – – Company strongly encourages stockholders holding unvoted...
Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
June 04, 2021 07:30 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., June 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
June 03, 2021 10:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 27, 2021 07:30 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., May 27, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021 07:30 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
Notice of Settlement of Derivative Actions
May 26, 2021 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE IN RE ZYNERBA PHARMACEUTICALS, INC. DERIVATIVE LITIGATIONLead Case No....
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
May 17, 2021 08:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
May 12, 2021 06:45 ET
|
Zynerba Pharmaceuticals, Inc.
– RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, expected to be initiated in the third quarter of 2021 – – Cash runway well into first half 2024; $93.1 million at March 31,...
Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome
May 05, 2021 16:05 ET
|
Zynerba Pharmaceuticals, Inc.
- Confirmatory pivotal trial expected to be initiated in the third quarter of 2021 - - Zynerba to hold conference call today, May 5, 2021 at 5:30 pm ET - DEVON, Pa., May 05, 2021 (GLOBE NEWSWIRE)...